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Abstract
T-cell precursors remain developmentally plastic for multiple cell generations after entering the
thymus, preserving access to developmental alternatives of macrophage, dendritic cell, and even
mast-cell fates. The underlying regulatory basis of this plasticity is that early T-cell differentiation
depends on transcription factors which can also promote alternative developmental programs.
Interfactor competition, together with environmental signals, keep these diversions under control.
Here the pathways leading to several lineage alternatives for early pro-T cells are reviewed, with
close focus on the mechanisms of action of three vital factors, GATA-3, PU.1, and Notch-Delta
signals, whose counterbalance appears to be essential for T-cell specification.
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1. MODELS FOR HEMATOPOIETIC LINEAGE CHOICE
Hematopoietic stem cells can develop into any of at least ten different kinds of effector cells,
and these can be grouped broadly into lymphoid, myeloid, erythroid, megakaryocytic, and
other types. Stem cells become particular cell types by passing through sequences of partially
restricted, but still pluripotent intermediates. The outcome of competing regulatory forces at
work on the cells during the partially restricted intermediate stages ultimately forms the basis
for the commitment decision and controls differentiation. In this review, we will discuss how
this works as revealed in cells making the choice between the T-cell fate and its developmental
alternatives.
Particular transcription factors can drive specific hematopoietic lineage choices. An example
is the way erythro-megakaryocytic lineages separate from myeloid lineages (rev. by [1]). Here,
the zinc finger factor GATA-1 apparently drives erythro-megakaryocytic fates in opposition
to the E26 transformation-specific (Ets) family factor PU.1, whereas PU.1 plays a dominant
role to direct myeloid fates in opposition to GATA family factors [2–6]. Downregulation of
PU.1 in hematopoietic precursors provides one of the earliest indices that cells have undertaken
an erythro-megakaryocytic lineage pathway [7,8]. In another dichotomy, Notch signals that
activate the RBPJ transcription factor (also known as CSL, for CBF-1, Suppressor of Hairless,
Lag-1) are pitted against the activity of the Paired-homeodomain transcription factor Pax5.
Corresponding Author: Ellen V. Rothenberg, Division of Biology 156-29, California Institute of Technology, Pasadena, CA 91125 USA,
Tel: (+1) 626-395-4992, Fax: (+1) 626-449-0756, E-mail: evroth@its.caltech.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Semin Immunol. Author manuscript; available in PMC 2009 August 1.
Published in final edited form as:
Semin Immunol. 2008 August ; 20(4): 236–246. doi:10.1016/j.smim.2008.07.006.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Notch activation triggers and sustains the T-lymphocyte program while blocking the B-
lymphocyte program, whereas Pax5 directs the B-cell program while blocking the T-cell
program, in part by inhibiting Notch1 expression [9–11]. As these oppositions suggest, the
dominance of each of these factors in a particular pathway is ultimately based not only on its
ability to activate cell-type-specific genes, but also on its ability to repress or inhibit any factors
important for alternative pathways (rev. in [12]).
The discovery of partially restricted progenitors, stable enough to identify and isolate
prospectively, marked a profound advance toward understanding how hematopoietic lineage
choice occurs [13–15]. The existence of these restricted progenitors revealed that when cells
depart from the stem cell state they are not yet committed to adopt one particular developmental
fate. Rather, they begin differentiating while equipped with a regulatory apparatus that could
support any of several alternative fates. This suggests that fates may be grouped based on
relatedness of the gene expression programs they activate, a grouping that ought to be reflected
in the modes of action of their dominant transcription factors.
The exact relationships between these powerful regulators, in action, depend on whether
lineage decisions are strictly hierarchical or not, with potential for more similar fates being
combined longer than potential for more distinct fates. The notion that lymphocytes derive
from a common lymphoid precursor and myeloid cells from a common myeloid precursor has
been highly appealing. However, in a challenge to the hierarchical models, there is now
abundant evidence that most T lymphoid precursors lose B lymphoid developmental potential
earlier than they lose myeloid potential [16–19]. Most radically, T-cell development – like
dendritic cell development – may not even be required to pass through a unique sequence of
intermediates [20–25]. This can be explained by the fact that the essential T-lineage
developmental program depends on a substantial overlapping of activities between
transcription factors that are “T-cell specific” and factors capable of driving other fates (Figure
1). The specification of particular hematopoietic cell types by shifting, overlapping
combinations of lineage-nonspecific factors has been noted for other lineages [26], and in all
such cases it can only work if there is precise quantitative and stage-specific regulation of the
factors involved to enable differentiation to progress. This overlap and mutual constraint is
vividly illustrated in the relationships between three essential factors, Notch, PU.1, and
GATA-3, during early T-cell development.
2. LANDMARKS FOR EARLY T-CELL DEVELOPMENT
Early-stage T-cell precursors are partially restricted cells that migrate to the thymus either just
after or immediately before losing the ability to give rise to B lymphocytes, but before they
shut off molecularly distinct developmental alternatives including macrophage or dendritic-
cell fates. Differentiation of these cells occurs in the thymic cortex over a period of many days
and is accompanied by a flexible degree of proliferation. Fig. 2 summarizes the cell-surface
and molecular phenotypic criteria that distinguish mouse thymocytes in successive stages
toward T-lineage commitment [27–34].
The earliest thymic subset, Early T-cell precursors (ETP) or “DN1” cells (CD3−, CD4−,
CD8−, c-Kithi, CD44+, and CD25−)1, can undergo extensive intrathymic proliferation,
especially in adult animals. But throughout this proliferation ETPs remain uncommitted to the
T lineage, as they retain efficient competence to develop into natural killer, macrophage, and
dendritic cells [16–19,35]. Transcription of Rag1, Rag2, and many T-lineage-specific genes is
low or undetectable at the ETP stage. Then, a broad increase in T-lineage-associated gene
1“ETP” is used here instead of “DN1” because the classically defined DN1 thymocyte population (CD44+ CD25−) includes a majority
of cells that are not T lineage precursors.
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expression begins as the cells pass to the next stage, called DN2 (CD3−, CD4−, CD8−, c-
Kit+, CD44+, CD25+). Still, many uncommitted cells remain in the DN2 population, exhibiting
dendritic-cell, macrophage, and NK potential, and some cells in the DN2 population can even
develop into mast cells [36]. However, these alternatives disappear completely as the cells
progress further to the DN3 stage (CD3−, CD4−, CD8−, c-Kitlow, CD44low, CD25+). DN3 cells
express a full panoply of T-cell specific genes, indicating the maximal activation of positive
regulators of T-lineage identity. At this stage, expression of Rag1 and Rag2 is fully upregulated,
most cells slow or stop their proliferation, and the first complete rearrangements of TCRβ,
TCRγ, and TCRδ genes occur. If successful, these rearrangements enable the cells to assemble
a pre-TCR (rearrranged TCRβ + invariant pre-TCRα) or TCRγδ complex at the cell surface,
and these complexes trigger signals that enable the cells to undergo β-selection or γδ-selection,
respectively.
The stages of intrathymic development that lead up to β-selection (ETP to DN3) can be
described as pro-T cell stages. T-cell development through these stages depends on a set of
regulators that include both T-cell specific and shared transcription factors (Fig. 1)[30,32,37–
42]. The T-cell specific transcription factors GATA-3 and TCF-1 are transcriptionally induced
from a low level in prethymic precursors to a substantial level as early as the ETP stage, with
further increase to the DN3 stage [43–47]. Another crucial transcription factor, the basic helix-
loop-helix transcription factor E2A, is strongly upregulated through stabilization at the protein
level, starting at the DN2 stage [48,49].
At the same time, a rich legacy of transcription factor gene expression inherited from stem cell
precursors continues throughout early stages of T-cell development [43,46,50]. Some
prethymically expressed factors are maintained all the way through lineage commitment (E.-
S. David-Fung et al., unpublished results), and several regulators crucial for T-cell
differentiation have stem cell provenance; e.g. Myb, Runx1, Ikaros, and Gfi-1 [51].
Nevertheless, there are also parts of the stem cell legacy that must be downregulated in a
precisely staged way in order to allow T-cell development to proceed. The ETP population
retains strong expression of a number of stem cell associated factors, among them PU.1 and
SCL, and at least in some ETP cells, GATA-2 and/or C/EBPα as well [52–55]. All of these
genes are shut off by the DN3 stage. PU.1, C/EBPα, and GATA-2 can all promote non-T fates
when overexpressed [36,53,54,56–59], and their precisely regulated repression is important
for lineage commitment, as discussed below.
3. CONTROL OF EARLY T-CELL DEVELOPMENT BY EXTERNAL SIGNALS
T-lineage specification is driven and maintained by signals from the environment. The
transition from each DN stage to the next depends on the existing internal transcription factor
complement in the cell together with changes in transcription factor function induced by
external environmental signals. The most important of these signals, on current evidence, are
cytokine signals, signals through the Wnt-β-catenin-TCF pathway, and repeated signals from
the Notch pathway. As for other hematopoietic lineages, receptors for trophic signals are highly
regulated in T-lineage cells and only select receptors are expressed.
For survival and proliferation, the earliest T cell precursors may rely on signaling through the
cytokine receptor c-Kit [60], but also from ETP stage through the end of DN2 stage they are
dependent on IL-7/IL-7R signals [61]. Among the transcription factors required at these stages,
recent evidence suggests that the Runx family factors may help establish appropriate levels of
proliferation through their impact on IL-7R expression and function [62,63]. Proliferation may
compete with differentiation, especially for adult-derived immature thymocytes, as high-level
IL-7/IL-7R or c-Kit signaling is seen to retard progression from DN2 to DN3 stage even while
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it promotes expansion [23,64,65]. However, these cytokine signals do not appear to promote
differentiation, and are not sufficient to maintain viability without additional survival signals.
Wnts are suspected to be another part of the survival signal. This inference is based on the
importance of the TCF-1 transcription factor and its relative LEF-1, which are the
transcriptional effectors of the Wnt canonical signaling pathway. Both of these transcription
factors are converted from repressors to activators by β-catenin, which is mobilized by signals
from the canonical Wnt pathway. Activity of TCF-1 or LEF-1 is essential for passage through
β-selection, and TCF-1 also plays a critical, nonredundant role in adult thymocytes in
progression from ETP to DN2 [47,66,67]. TCF-1 target genes in thymocytes include many
survival and proliferation genes [68]. It is supposed that most TCF/LEF functions are Wnt
dependent, based on the severe developmental blocks caused by transgenic expression of Wnt
inhibitory proteins, Dickkopf and ICAT [69,70]. However, the connections between the initial
Wnt input, the effector function of TCF-1, and the β- or γ-catenin proteins that normally act
as intermediates have remained somewhat difficult to parse. Forced activation of β-catenin in
progenitor cells apparently causes them to arrest development in a multipotent stage and reverse
commitment, rather than enhancing their commitment to the T-cell fate [71–73]. New data
suggest that hematopoiesis and apparently normal T-cell development can occur even in the
absence of both β- and γ-catenin [74], suggesting that some roles for TCF/LEF family
transcription factors could depend on other mediators. This ambiguity raises the question of
whether TCF-1 in DN2-stage cells could actually be playing an important role as a repressor
rather than as an activator. If so, one potential repression target implicated at this stage is the
PU.1 gene [75].
The most dominant environmental factor in T-cell specification is the availability of ligands
for the transmembrane receptor, Notch. As reviewed elsewhere in detail, interaction between
Notch1 and its ligands of the Delta-like class is a distinctive requirement for precursors entering
and pursuing the T-cell pathway, from the generation and maintenance of ETPs all the way to
the beginning of β-selection (see reviews [9,10,28,31,76–78]). Notch-Delta signaling
contributes not only to T-lineage survival and growth but also to lineage choice. Notch-Delta
signaling favors T-cell development and blocks B-cell development from multilineage
prethymic precursors; then, even after B-lineage potential is permanently suppressed, it blocks
ETP and DN2 cells from access to all other physiological alternatives to T-lineage choice
[16,35,79,80].
4. CONTEXT-DEPENDENT MODULATION OF NOTCH SIGNALS
Notch signaling is not a Boolean operator that determines T-lineage fate at a stroke, but a
quantitatively modulated participant in protracted lineage decisions. A sustained succession of
interactions with Delta-class target ligands, through all the cell cycles from ETP throughout
DN2 stages, is needed to elicit full commitment to the T lineage [35,36,45,81]. Notch/Delta
interaction can drive many different starting populations of hematopoietic precursors into T-
cell development [21,23,36], but the dosages required are subject to distinct thresholds at
different stages [82–84], and different Notch-triggered effects require different signal
intensities. Prethymic precursors from bone marrow require substantially higher levels of
Notch signaling than even the earliest intrathymic precursors to initiate T-cell development in
vitro [84]. However, only a low level of Notch signaling is needed to suppress and eliminate
the B-cell option [35,81], while a stronger Notch signal intensity is needed to block the
dendritic-cell and natural killer cell fate options [35,83,85]. ETP and the earliest fetal thymic
immigrants begin T cell development in a Notch “primed” state, already showing upregulation
of Notch target genes very early after entering the thymus [44,82,84,86,87]. Yet known Notch
target gene expression peaks at the DN3 stage [43,88,89]. It is not clear yet which this
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apparently amplified response reflects: stronger Notch-Delta signals, or interaction of constant-
level Notch signals with a developmentally altered regulatory context.
The biochemical mechanisms through which cells detect and respond differentially to different
levels of Notch pathway signals are still being investigated. Notch engagement triggers
proteolytic release of the intracellular domain of Notch, which moves to the nucleus and
provides an activation domain for the pre-existing transcription factor RBPJ (CSL). Recent
data provide a possible mechanism to make certain target genes more sensitive than others to
the strength of Notch signaling. Head to head CSL binding sites, called SPS (sequence paired
sites), preferentially direct cooperative assembly of transcriptionally active complexes of
RBPJ, intracellular Notch, and the coactivator MAML1 as compared to single sites for RBPJ
[90]. This suggests a mechanism for translating strength of Notch signaling through to the
target gene. Furthermore, such SPS sites may favor cooperation with basic helix-loop-helix E
proteins bound at neighboring elements [91]. Such cis-regulatory elements could structurally
underlie the responses that depend on Notch-E protein cooperation [92] at many early stages
of T-cell development[93]. At the same time, Notch signaling is highly modulated by
antagonistic transcription factors such as LRF, or Zbtb7a [94]; by antagonists of MAML1
assembly like Msx2-interacting protein (MINT)[95]; and by feedback from negative regulators
of the cytoplasmic part of the cascade such as Deltex1 and Nrarp [96,97]. One further way in
which the Notch signal could be regulated to achieve gradations of signal strength and duration
is by diversity in the sites of S3 cleavage of Notch [98]. This generates two types of Notch
intracellular domain, one more stable than the other, with a resulting effect on intensity of
transcriptional response.
In the past two years, Notch signaling has been suggested to affect T-lineage gene expression
through yet additional pathways, and this is through gene-specific modulation of the effects of
other transcription factors. Although the biochemical mechanisms remain to be determined,
Notch pathway mediators can also modify the activities of GATA-3 and PU.1 as discussed
below, effectively restraining their abilities to promote non-T fates.
5. ESSENTIAL ROLES FOR GATA-3 AND PU.1 IN EARLY T CELL
DEVELOPMENT
Both GATA-3 and PU.1 are essential for T-cell development. GATA-3, a double zinc finger
(C4-type) transcription factor, is expressed in an almost T lineage-specific pattern among
hematopoietic cells. It is turned on among the earliest genes activated by Notch-Delta signaling
in hematopoietic precursors, and is used throughout T cell development from the ETP stage
all the way to post-thymic responses to antigen. The ETS-family transcription factor PU.1 is
almost the reverse, with virtually no expression in most thymocytes or mature T cells. PU.1 is
most prominent in B cells, multipotent hematopoietic progenitors, and myeloid cells of various
lineages, where it has well-documented positive gene regulatory activities. The competitive
antagonism between PU.1 and GATA family factors is thought to control myeloid vs. erythro-
megakaryocytic fate decisions as already noted, and so a simple expectation would be that
GATA-3 might dictate T-lineage fate while PU.1 should oppose it. Nevertheless, substantial
expression of GATA-3 and PU.1 RNA overlaps in ETP and DN2 stage thymocytes.
The loss of GATA-3 at the germline or stem-cell stage eliminates all recognizable T-cell
precursors at least as early as the DN2 stage [99–101]. If GATA-3 is conditionally deleted
later, at different times after thymic entry, powerful effects are seen at multiple later stages of
T-cell development (rev. by [38]). Similarly, germline disruption or early conditional deletion
of PU.1 eliminates most or all T cell development [102–105]; a severe hypomorphic allele also
causes profound inhibition of fetal T-cell development [106]. Because PU.1 expression in T-
lineage cells is confined to the earliest DN stages, the knockout phenotype is also abnormal in
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early stages. PU.1 is needed for generation of precursors with the ability to migrate to the
thymus; it is not yet clear for how long after their arrival intrathymic intermediates require PU.
1 as well. However, throughout the extensive intrathymic proliferation by ETPs, these cells
maintain a level of PU.1 expression similar to those found in multilineage prethymic precursors
and stem cells [7,8,43,107], arguing for a continuing intrathymic role.
The target genes that GATA-3 and PU.1 are needed to regulate at these early stages are not
clearly identified, in part because so little is known about the requirements of cells so close to
the stem-cell stages. The blocks caused by losses of these factors long precede the blocks that
are seen at β-selection due to lack of TCR rearrangements or any of the signaling components
that transduce TCR signals. Thus, most T-lineage genes that have been suggested as targets
for GATA-3, including the Rag recombinases, TCR genes, CD5, and the Th2 cytokine
complex, are unlikely to account for its early essential role (see [38] for review). Both GATA
factors and PU.1, however, can positively or negatively affect expression of the two most
important growth factor receptors used in ETP and DN2 cells, namely c-Kit and IL-7Rα [36,
108–112]. These results raise the possibility that balanced activity of GATA-3 and PU.1 is
primarily needed in early thymocytes to support survival and growth.
The paradigm of competition between PU.1 and GATA factors in erythromyeloid development
might make this cooperative action seem surprising, but it is not exceptional. First, the mutual
interference that occurs between PU.1 and GATA factors is at the level of protein/protein
interaction. This kind of mechanism should depend on diffusion, and should not benefit from
specific co-recruitment to neighboring DNA sites to accelerate interaction. Therefore,
interference should be highly concentration-dependent, and as long as both PU.1 and GATA
protein concentrations are below a certain threshold, they may not interfere in fact. Second,
there may be steric constraints to the antagonism between PU.1 and GATA factors at target
genes where both factors engage DNA simultaneously. For example, the inhibition of PU.1
transactivation by GATA-1 depends on an interaction between the DNA binding domains of
the factors, the Ets β3-β4 region of PU.1 with the C-terminal zinc finger of GATA-1 [4,113],
whereas the inhibition of GATA-1 DNA binding by PU.1 requires polarized binding of the
PU.1 N-terminus to the GATA-1 C-terminal finger [114]. There is clearly no antagonism at
some mast-cell lineage target genes that depend on simultaneous GATA and PU.1 binding
[115]. Thus, balanced activity of GATA-3 and PU.1 could selectively promote expression of
a particular subset of target genes that respond to both factors, while inhibiting expression of
targets that respond to one or the other exclusively.
6. GATA-3-DRIVEN LINEAGE INFIDELITY: DOSAGE AND NOTCH
SENSITIVITY
With its T-lineage specific expression and recurrent T-lineage roles, GATA-3 has been an
appealing candidate for a factor conferring T-lineage identity in early thymocytes (Fig. 1B).
However, gain of function of GATA-3, in the presence or absence of Notch signals, fails to
enhance either appearance or developmental progression of the earliest T-lineage cells [36,
111,116,117]. Only around the time of lineage commitment, from the DN3 stage or its human
equivalent onward, does high-level GATA-3 become compatible with modulation of fates
within the T lineage [38,116,118–120]. Thus, high-level GATA-3 is inhibitory for some of the
same stages of T-cell development that require normal levels of GATA-3. GATA family factors
can activate a cell-cycle arrest mechanism [121,122], and so one possibility would be that
excessive GATA-3 simply causes loss of cellularity. Indeed, high-level GATA-3 can inhibit
survival of later-stage thymocytes, and a conserved KRR motif within GATA-3 specifically
mediates this cytostatic activity [123]. However, this is not the only cause of interference with
early T-cell precursors. High-level GATA-3 actually promotes an alternative, non-T lineage
choice. The effects of high-level GATA-3 are context-dependent: whereas it can promote a
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megakaryocytic fate from bone marrow stem cells [117], it specifically drives a mast-cell
development program when expressed in early T-lineage cells [36] (Figure 3).
This lineage diversion is interesting for three reasons. First, the mast-cell program has not
previously been shown to be related to any lymphoid program [124–126], and so its activation
within T-lineage precursors by a “T-lineage-specific” transcription factor is remarkable.
Second, the ability of thymocytes to respond to GATA-3 in this way is developmentally
regulated, observing the same commitment boundary as other non-T fates. While ETP and
DN2 stage cells can respond to GATA-3 in this way, DN3 cells cannot. This suggests that the
diversion depends on additional intrinsic features of the earliest-stage cells which may be lost
with commitment. Finally, the mast-cell pathway is effectively blocked in thymocytes by Notch
signaling. When Notch-Delta interaction is also occurring, high-level GATA-3 simply blocks
survival, and the mast-cell program cannot be completed [36].
Respecification is a slow, multistep process [36], as diagrammed in Fig. 3. Overexpression of
GATA-3 in fetal thymocytes causes a number of early gene regulatory effects within the first
40 hr, but it does not materially alter the expression of most T-cell differentiation markers or
regulatory genes. Among the most pronounced early changes are a strong, temporary
downregulation of PU.1 (in the ETP and DN2 cells) and upregulation of the mast-cell
transcription factor MITF (microphthalmia associated transcription factor) and the two other
hematopoietic GATA factors, GATA-1 and GATA-2. These effects occur concurrently with
a strong upregulation of c-Kit expression and can be detected, more or less, whether Notch
signaling is present or not. Over the next days, further changes occur to activate an increasing
set of mast-cell genes, including those encoding transcription factors SCL (Tal1) and Gfi-1b,
while T-lineage-specific gene expression becomes increasingly broadly inhibited. The
emergence of viable converted cells now depends on removal from Notch-Delta signals. It is
likely that the additional steps depend on the newly induced (or reinduced) transcription factors
as well as on GATA-3 itself (Fig. 3). The distinctness of this stage is reflected in restored
expression of PU.1, to levels appropriate for the mast-cell fate [127]. However, there is still a
substantial “hangover” of expression of a few T-cell genes, such as CD3ε and CD3γ, even in
the cells that have undergone complete phenotypic conversion to c-Kithigh Thy-1low CD27−
mast-cell precursors. Full maturation to a surface FcεRI+ state depends on further culture in
mast-cell cytokines for at least another week (Fig. 3).
Under normal circumstances in the bone marrow, the crucial transcription factor for initiating
mast-cell development is GATA-2 [125,128]. GATA-3 overexpression has similar or identical
effects to forced expression of GATA-2 in early thymocytes, consistent with the extensive
structural similarities between these related factors [36]. Thus GATA-3 probably opens up
access to the mast-cell pathway by activating genes that are normally regulated in bone-marrow
precursors by GATA-2. But the interesting point is that GATA-3 is normally a participant in
the T-cell program, not the mast-cell program, and a collaborator with Notch signaling, not an
antagonist. In the unstable developmental context of early T-lineage cells, its entire
developmental impact on the cells depends on its level of expression. Thus avoiding excessive
induction of GATA-3 in the ETP and DN2 stages is as important for T-cell development as
guaranteeing that some GATA-3 will be present.
It remains to be determined how the committed state of DN3 cells blocks access to the mast-
cell program. But how does Notch signaling prevent this lineage choice in the ETP and DN2
stages? All of the short-term effects of GATA-3 are slightly stronger when Notch signals are
removed [36]. High-level GATA-3 actually appears to blunt Notch1 expression itself as well
as the expression of certain Notch target genes, suggesting a competitive mechanism, but most
T-cell transcription factors are minimally affected by GATA-3 overexpression, with or without
Notch-Delta signaling. The largest Notch-dependent difference in GATA-3 effects that can be
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noted at this early point is that TCF-1 is repressed only when Notch signals are absent. Thus,
Notch signaling may indirectly be acting either to maintain the transcriptional effector of the
Wnt-β-catenin pathway, or else to preserve a repressive function of TCF-1 which may be
important for T-lineage fidelity in this case. TCF-1 and increasingly LEF are then severely
repressed in later stages of the conversion to a mast-cell precursor state [36]. If these factors
are serving in thymocytes as repressors of PU.1 expression [75](see above), then their own
downregulation as the cells become fully converted mast-cell precursors may help to explain
why PU.1 expression resumes [36](Fig. 3, dashed lines). These results suggest that GATA-3
is linked with Notch signaling, TCF/LEF factors, and PU.1 in a network of dose-dependent,
competitive interactions that determine access of early T-cell precursors to the mast-cell
developmental pathway.
7. PU.1 AND MYELOID ALTERNATIVES TO THE T-LINEAGE PROGRAM
Although needed to start T-cell development, PU.1 also helps to maintain a progenitor-like
developmental plasticity in the ETP and DN2 cells. During commitment, expression of PU.1
and SCL (Tal1) precipitously shuts off [129,130]. Forced gain of PU.1 function, beyond the
stage when it is normally shut off [53,54,56–58,111], provides evidence that endogenous PU.
1 expression in earlier T-cell precursors is probably rate-limiting for their developmentally
regulated access to macrophage and dendritic-cell fates.
Forced PU.1 expression can undo the commitment of DN3 thymocytes and convert them to
myeloid dendritic cell phenotype, passing through dual-lineage phenotypic intermediates that
clearly show the transdifferentiation in progress [54,56–58](Figure 4). High-level,
dysregulated PU.1 expression can inhibit growth under “lymphoid” cytokine conditions, but
the converted cells thrive if myeloid growth factors are supplied [54] or if the cells express a
Bcl2 transgene [57,58]. The mechanism PU.1 uses to promote these alternative fates appears
to be intrinsically Notch-sensitive. Notch-Delta signaling can restrain exogenous PU.1 from
causing respecification of DN2 or DN3 cells [54,58](Fig. 4), even when forced expression of
PU.1 reaches levels more than ten times higher than normal ETP or DN2 levels. The important
feature of this antagonism is that Notch signaling does not directly inhibit expression of PU.1
itself, while PU.1 also does not appear to inhibit Notch1 or Notch3 expression directly, at least
not when overexpressed in DN2 or DN3 stage cells [58]. Thus PU.1 as expressed in DN2 cells
should be a conditional mediator of lineage plasticity, which ideally positions the cells in a
regulatory state where responses to microenvironmental Notch signals can dictate their fates.
Even in the DN3 stage, the committed state remains intrinsically rather flimsy with respect to
myeloid and dendritic-cell alternatives. Other exogenous genes can also undo the commitment
of DN3 cells. Forced expression of the myeloid factor C/EBPα or its relative C/EBPβ can also
respecify DN3 cells to myeloid lineage cells very efficiently, to an inflammatory macrophage
fate rather than a myeloid dendritic cell fate [54](Fig. 4). Furthermore, surprisingly, DN3 cells
that have downregulated PU.1 express peak levels of the PU.1 relative Spi-B, and yet if
artificially expressed at sufficiently high levels, Spi-B itself can also cause conversion of the
cells to a dendritic-cell phenotype [56]. Thus the commitment of normal DN3 cells may be a
composite of the recent repression of PU.1, absence of C/EBP factors, quantitative limits on
the expression of Spi-B, and the relatively weaker myeloid-promoting potency per molecule
of the Spi-B which they do express. Spi-B expression here may provide the cells with
continuation of any T-lineage promoting functions that PU.1 formerly may have served; for
example, PU.1 (and probably Spi-B) may actually upregulate expression of the T-lineage
markers Cd25 and Ptcra [57,111,131].
Somewhat like PU.1, C/EBPα effects on DN3 cells are blunted by Notch signaling [54].
However, C/EBPα has a much more direct antagonistic effect on expression of Notch1 itself.
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Preliminary evidence suggests also that Notch-Delta signaling may actively inhibit C/EBPα
expression in immature fetal thymocytes, implying a more direct binary opposition than that
of Notch and PU.1 [36,58]. Thus, sustained C/EBPα expression would be incompatible with
passage through the Notch-dependent early stages of T-cell development. Indeed, endogenous
C/EBPα may very well contribute to the robust myeloid potential of many ETPs, but its
expression is already very low by the DN2 stage [54,132](E.-S. David-Fung & E. V. R.,
unpublished results). However, even in DN2 cells reinduction of C/EBPα can be triggered by
ectopic growth factor receptor stimulation [59], especially in the absence of Notch signaling.
It is likely to be the combination of this upregulated C/EBPα with endogenous PU.1 that
explains why ectopic growth factor receptor signaling is sufficient to drive ETP and DN2 cells
into myeloid lineage conversion [79,133].
Both C/EBPα and PU.1 drive pro-T cells to myeloid identities through paths of several distinct
steps over a period of days (Fig. 4). Each of these steps represents a potential opportunity for
regulatory intervention, either by Notch signals or by other signaling pathways. Strikingly, and
in contrast to GATA-3 promoted lineage diversion, both myeloid factors start by undermining
T-lineage identity, through downregulation not only of differentiation genes but also of
multiple DN3-expressed regulatory genes. C/EBPα represses Notch1, GATA-3, and E2A,
while PU.1 represses Myb, TCF-1, Gfi-1, E proteins, certain other Ets family transcription
factors, and Ikaros [54,57,58]. Some myeloid gene expression also begins. Then, to complete
the transformation, each of these factors can reactivate the other’s expression after several days
in the absence of Notch signals [54,58](Fig. 4). These cross-activations of myeloid regulators
do not precede, but rather follow, the downregulation of T-cell regulatory factors. When Notch
signaling neutralizes the effects of high-level PU.1, its effects are mostly to protect the
expression of these T-lineage transcription factors rather than to block the earliest increases in
myeloid-associated gene expression [58](Fig. 4, “+DL”). Later, C/EBPα reactivation may be
inhibited in thymocytes receiving Notch signals [36,58], but it is not clear whether the effect
is direct. This raises the possibility that among the T-cell factors that are initially targeted, there
are Notch-dependent “gatekeeper” functions that would otherwise restrain the cells from the
myeloid program, and that these functions need to be disabled before trans-differentiation can
proceed.
PU.1 and C/EBPα do not reach the point of positive cross-regulation by a common route.
Because these two factors have divergent initial effects on Notch, GATA-3, and Myb [54,
58], the early intermediates in lineage conversion should be quite different (Fig. 3A). This is
strikingly reminiscent of a recent report that forced sequential expression of GATA-2 and C/
EBPα in common lymphoid progenitors, a “tabula rasa” cell type, leads to highly biased
generation of either eosinophils or basophils, with the whole developmental outcome
depending on the order in which these factors act [125]. The C/EBPα-driven program is
therefore a different lineage alternative for DN3 cells than the pathway activated by PU.1.
When artificially overexpressed, C/EBP factors can even force DN3 thymocytes to adopt a
form of myeloid fate after their endogenous PU.1 genes have been excised [54]. The fact that
these different myeloid pathways are just one gene away for DN3 cells shows that these newly-
committed cells differ in relatively few respects from the regulatory state and gene accessibility
pattern of multipotent precursors.
8. GATA-3 AS ANTAGONIST OF MYELOID LINEAGE OPTIONS
The functions mobilized by Notch to preserve T-lineage identity before lineage commitment
need to be identified. GATA-3 is an obvious candidate for one of the T-lineage gatekeeper
functions that antagonizes myeloid fates under normal conditions. Myeloid lineage conversion
of thymocytes by either C/EBPα or PU.1 is inhibited if GATA-3 is co-expressed [54,134].
Furthermore, GATA-3 may be suspected of a role in lineage commitment itself, as
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overexpression of GATA-3 in early fetal thymocytes efficiently downregulates PU.1 RNA
expression as already noted [36,111,118]. GATA-3 itself is encoded by one of the genes that
is turned on earliest in progenitors as they begin the T-cell developmental program in response
to Notch-Delta signaling. GATA-3 is also a direct target of Notch induction in the context of
T helper 2 cells [135,136]. Therefore GATA-3 might be implicated in aspects of the Notch-
dependent protection of developing T cells from myeloid diversion by PU.1 or C/EBPα.
In reality, the interplay between GATA-3 and myeloid determination is probably more subtle.
Whether or not GATA-3 is able to protect cells from myeloid differentiation is very much
dependent on cellular context and probably also dependent on its exact level of expression.
Indeed, in non-T lineage cells GATA-3 can even trigger myeloid development, as observed in
Pax5-deficient pro-B cells [137]. The simplest case of GATA-3 blocking the myeloid fate may
be when C/EBPα expression is imposed on DN3 cells [54]. Here, one of the earliest effects of
C/EBPα or C/EBPβ seems to be downregulation of GATA-3. Adding back GATA-3 can
therefore be seen as an epistasis test, in which exogenous GATA-3 can restore the missing
function. Coexpressed GATA-3 can block Mac-1 (CD11b) upregulation by C/EBPα, an aspect
of the C/EBPα response that appears to reflect cross-induction of PU.1, and this inhibition is
consistent with the ability of high GATA-3 to block PU.1 expression [36,111,118]. Even here,
however, there is not clear evidence how much of the T-cell program GATA-3 can restore. For
example, it is not clear whether GATA-3 can prevent C/EBPα from downregulating Notch and
E protein expression [54], which would independently be required for full T-cell development.
As an antagonist for PU.1, the possible role of GATA-3 is more complex. High-level PU.1,
unlike C/EBPα, has little immediate effect on expression of GATA-3 itself or of Notch1. When
PU.1 effects are neutralized by Notch signaling, again there is little if any impact on levels of
GATA-3 RNA; instead, the strongest protective effects are seen on RNAs encoding a
completely different set of T-lineage regulators: Myb, E proteins, Gfi-1, and Bcl11b [58].
TCF-1, also downregulated by PU.1, is also partially protected by Notch signaling. Thus, when
GATA-3 is co-expressed with PU.1, it is probably antagonizing PU.1 in a supraphysiological,
gain-of-function mode. Thus, it is possible that GATA-3 coexpression with PU.1 does not
really restore the T-lineage program but simply provides antagonism for PU.1 by titrating it at
the protein level, preventing PU.1 from transactivating the myeloid genes. However, the
biochemical basis for these effects remains unresolved. Many of the most immediate impacts
of PU.1 on pro-T cells are the repression of critical T-cell genes. Yet GATA factors are not
thought to block PU.1 binding to DNA, but simply PU.1 transactivation; it is completely
unclear what effect they would have on any target genes where PU.1 acts as a direct repressor.
Ultimately, GATA-3 may only be one part of the mechanism antagonizing myeloid fates in
developing T cells. Under normal circumstances, GATA-3 could also play a role in the
programmed downregulation of PU.1 itself (D. D. S.-A., unpublished results), although current
published evidence suggests that the normal control of PU.1 levels in developing thymocytes
may be more affected by inputs from TCF/LEF family and Runx family transcription factors
[75,138]. On the other hand, the abilities of the myeloid transcription factors to repress
Gata3 expression or block GATA-3 DNA binding could play a substantial role in the timing
of T-cell developmental progression, as discussed in the final section.
9. TRANSDIFFERENTIATION, NOT DEDIFFERENTIATION, IN RESPONSE TO
REGULATORY PERTURBATION
Neither myeloid nor mast-cell programs are thought to be closely related to lymphocyte
developmental programs, and indeed, conversion of thymocytes to dendritic cells by PU.1,
inflammatory macrophages by C/EBPα, and mast cells by excess GATA-3 all involve a
repression of T-lineage specific gene expression. Their diversionary activity is even more
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remarkable in view of the positive roles that two of these diversion-inducing factors normally
play in T-cell development, when expressed at different times and levels. This raises the
question of whether the effects of these factors are simply to cause T-cell precursors to revert
to a more primitive, multipotent progenitor state, from which all these diverse pathways
naturally emerge.
The question is more interesting because recent data indicate that in vivo, PU.1 downregulation
coincides with the main onset of T-lineage specific gene expression from the DN2 to the DN3
stage, linking a major positive regulatory event in the T-cell program with the loss of alternative
choices. T-lineage genes appear to be upregulated first in that subset of DN2 cells that have
already begun to downregulate PU.1 [129,139]. PU.1 acts as a transcriptional repressor of genes
encoding T-lineage transcription factors including TCF-1 and E proteins [58], and through
protein-protein interactions it could antagonize GATA-3 functions needed for progression to
the DN3 stage (D. D. S.-A. and E. V. R., unpublished results) as long as it is expressed.
Conceivably, some of these effects could be strong enough even in the presence of Notch
signaling to enable endogenous PU.1 to play a timing role for the triggering of particular aspects
of normal T cell development that depend on levels of E proteins, TCF-1, and GATA-3.
If excess GATA-3, PU.1, and C/EBPα each caused reversion to a multipotent progenitor state
before promoting redifferentiation, then the intermediate stages of the reconversion process
should go through a common stage. Furthermore, this common stage should be similar to the
phenotype of a natural multipotent progenitor. The transcription factor profile of natural
multipotent progenitors is marked by high-level coexpression of at least four informative
transcription factors: GATA-2, PU.1, SCL (Tal1), and Myb [43,140]. Indeed, forced high-level
GATA-3 turns on GATA-2 and SCL in thymocytes that no longer express these factors, and
it preserves the high-level Myb expression that thymocytes naturally share with progenitors.
However, it sharply downregulates PU.1, in contrast to normal progenitors. On the other side,
high-level expression of PU.1 in thymocytes fails to turn on GATA-2 (C. Franco & E. V. R.,
unpublished data) and actively represses Myb expression. Although the two perturbations have
in common an ability to downregulate TCF-1 (encoded by Tcf7), this too may go through
different pathways, as TCF-1 is almost completely protected from GATA-3 effects by Notch
signaling, while it is still inhibited by PU.1 in the presence of Notch-Delta signals. Thus the
intermediate regulatory states of the conversion process are completely different, and in both
cases they differ markedly from natural multipotent progenitors, and even from ETP
thymocytes. This shows that the paths to lineage diversion do not require backtracking to a
common multipotent state, but instead involve alternative, direct reprogrammings of
thymocytes from the midst of their T-lineage differentiation process.
10. CONCLUSIONS
The results reviewed here show that T-cell precursor specification is not only a protracted
process but a remarkably precarious one at the regulatory level. This makes sense of much
biology that could otherwise seem counterintuitive. An increasingly rich literature confirms
that most T-cell precursors naturally retain access to non-T and non-lymphoid programs well
beyond the stage when they have lost B-lineage potential [16–19,81,141–143]. The myeloid
developmental choices can be triggered even more readily in immature thymocytes before the
DN3 stage by manipulations that might have been imagined to leave the basic regulatory state
intact, such as stimulation through ectopic cytokine receptors [79,133]. Although the
divergence in gene expression program is less dramatic, until the DN3 stage these cells also
have access to the distinct natural killer pathway, which can be enhanced through antagonism
of E protein activity and/or removal of Notch-Delta signals [35,83,85,144–147]. This
simultaneous access to multiple distinct developmental programs can now be seen as the
consequence of a tug of war among regulatory forces acting normally within the cells between
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the ETP and the DN3 stage (Figure 5). Among the T, B, NK, mast, and dendritic-cell or myeloid
fates, the only one prohibited to T-cell precursors at an early stage is the B-cell fate, due to the
extreme incompatibility of initial B-cell specification with Notch signals. The other fates are
actually promoted by factors which also continue to have important roles in the T-lineage
pathway itself.
In this review, we have looked in detail at the interaction among three of these factors, PU.1,
GATA-3, and Notch, and to a lesser extent at roles of C/EBP factors and TCF-1/LEF family
members. The alternatives made available to early T-cell precursors by selective dysregulation
of these factors require several steps of reprogramming, but not a return to a stem-cell condition.
This is important because it shows that the dynamic balancing of these regulatory forces
maintains a degree of true multipotentiality that is inherent in T-cell precursor states throughout
the onset of T-lineage gene expression. Even in DN3 cells, where ectopic cytokine receptor
signaling, withdrawal of Notch signals, and GATA-3 overexpression are no longer capable of
causing respecification, reintroduction of C/EBP factors or PU.1 are sufficient to overcome
the fragile new state of commitment. Yet later, the lineage identity of a mature T cell in the
periphery is remarkably robust over arbitrarily large numbers of cell generations and through
many storms of activation-induced regulatory change, including high-level GATA-3
expression [38,148], intense MAP Kinase activation [149–151], frequent deprivation of Notch
signals, and even in some cases reinduction of PU.1 [152]. The contrast reveals that another
level of commitment must exist for T-cell precursors, possibly through an epigenetic
mechanism, which must occur after the DN3 stage and remains to be discovered and dissected.
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Figure 1.
T cell regulatory requirements in relation to other hematopoietic pathways. Schematic
summary of the transcription factor requirements for T-lineage specification from
hematopoietic stem cells (thick arrows), indicating alternative hematopoietic pathways that are
naturally promoted by the same factors (thin arrows). For reviews and updated references, see
[1,39,154–162]. Note that although GATA-3 is T-lineage specific under normal conditions
shown here, it is also capable of driving a non-T differentiation program even in early T-lineage
cells if expressed at an elevated level.
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Figure 2.
T cell developmental stages. Stages of early T-cell development in the young postnatal mouse
are shown in the context of their ordered migration through different compartments of the
thymus (rev. in [28,153]). Cells in the ETP and DN2 stages undergo extensive proliferation
(>10 cell cycles in all), and then the only other major phase of proliferation is immediately
following β-selection. To the left are shown the developmental fates that cells at each stage
can display if they are removed from the thymic microenvironment at the indicated stages.
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Figure 3.
Stepwise respecification of ETP and DN2 cells by GATA-3 overexpression. Early,
intermediate, and late stages in the reprogramming of ETP or DN2 cells by forced expression
of GATA-3. The stages where Notch signaling exerts inhibition are shown. Adapted from
Supplementary Figure 6, ref. [36]. Note that susceptibility of cells to these interactions is
limited to the stages before DN3, when an unidentified commitment function blocks access to
the mast-cell pathway.
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Figure 4.
Myeloid diversion pathways for advanced pro-T cells by re-introduction of C/EBPα or PU.1.
Comparison of the sequences of gene expression changes induced by transduction of pro-T
cells with PU.1 or with C/EBPα, from first effects (day 1–2) through lineage conversion (4–9
days). Effects summarized in the figure were measured on purified DN3 pro-T cells from adult
mouse thymus, transduced with C/EBP factors [54] or on DN2/3 stage fetal thymocytes,
transduced with PU.1 [58]. “Pro-T genes” include Rag1, Lck, LAT, and ZAP70, the products
of which are needed for TCR function. Continued progress along the myeloid pathway depends
on the lack of Notch-Delta signals in PU.1 overexpressing cells. The pathway branch indicated
by “+DL” shows how reintroduction of Notch-Delta signaling can stall or reverse the
reprogramming of fetal pro-T cells by PU.1. Although high-level PU.1 is inhibitory for
proliferation and progression of T-lineage cells beyond the DN3 stage, Notch signaling and
neutral viability support (a Bcl2 transgene) can restore substantial T-lineage differentiation
even beyond β-selection. Major gene targets that are differentially affected by PU.1 in the
presence or absence of Notch-Delta signaling are shown (data from ref. [58]).
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Figure 5.
Schematic of counterbalancing and dose-dependent regulatory forces that act on T-cell
precursors through the ETP and DN2 stages. Regulators named in red denote forces diverting
cells from the T-cell pathway. Of these, only EBF and Pax5 are not normally active in the
thymus during these stages. Notch signaling acts as a constraint on all of these alternatives.
This dynamic equilibrium is normally resolved at the DN3 stage, in part by the downregulation
of PU.1, but almost certainly through other regulatory changes as well [163].
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